Eat or Be Eaten

Doliveux, Roch
August 2006
Pharmaceutical Executive;Aug2006, Vol. 26 Issue 8, p96
Trade Publication
The article presents a perspective on the developments surrounding UCB. The initials UCB originally stood for Union Chimique Beige. Few years ago, sales were 50 percent pharmaceuticals, 50 percent chemicals. About 85 percent of our profits came from pharmaceuticals, and only 15 percent from chemicals. The company chose to focus on medicines, an industry that promises steady growth.


Related Articles

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.

  • UCB: set to expand its stake in the epilepsy market.  // PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p4 

    The article reports that the U.S. Food and Drug Administration has accepted the new drug application of UCB's Keppra XR tablets for the adjunctive treatment of partial onset seizures in adults with epilepsy. The reformulation is expected to maintain brand loyalty and to help the company retain...

  • FDA Approves Cimzia for Crohn's Disease.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p4 

    The article reports on the approval of UCB SA's Cimzia (certolizumab pegol), a PEGylated antitumor- necrosis-factor (TNF)-alpha antibody by the Food & Drug Administration (FDA) for Crohn's disease. It states that datum from Phase III pivotal studies presented patients with moderate to severe...

  • Pharma: Other News To Note.  // BioWorld Today;10/1/2013, Vol. 24 Issue 188, p15 

    This section offers news briefs related to pharmaceutical industry including the approval of UCB SA's Cimzia drug for psoriatic arthritis, and the plan of Vansen Pharma Inc. to offer its shares under a ticker symbol VNSN.

  • Global Report.  // Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p10 

    The article offers news briefs related to the pharmaceutical industry. The European Union (EU) will launch an investigation on pharmaceutical companies which stopped the launch of generic drugs. Reuters Ltd. has reported that GlaxoSmithKline is expecting that its sales in Asia Pacific will...

  • In search of “precision medicine”. Jones, Gareth // New Statesman;12/19/2014, p100 

    The article, a sponsored item published in partnership with pharmaceutical company UCB, looks at a November 2014 meeting sponsored by UCB and the research institute Reform which focused on British government science policies and trends in pharmaceutical research. It summarizes remarks of...

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: CNS;Dec2007, Vol. 6 Issue 12, p14 

    The article profiles UCB, a global biopharmaceutical company engaged in the research, development and commercialization of pharmaceutical and biotechnology products. It is said that in the epilepsy therapeutic category, the company markets brands such as Keppra and Nootropil. Moreover, for...

  • DATAMONITOR: UCB S.A.  // UCB SA SWOT Analysis;Jul2009, p1 

    The article presents a corporate profile of Brussels, Belgium-based biopharmaceutical company UCB SA. It offers details on the company's financial performance as of December 2008, business operations, markets, contact information and number of employees. An analysis of the company's strengths,...

  • Dr. Reddy's to acquire select products of Belgian firm, UCB.  // FRPT- Chemical Snapshot;4/19/2015, p14 

    The article reports that Dr. Reddy's Laboratories will purchase some products of biopharmaceutical firm UCB in Maldives, Sri Lanka, Nepal and India in April 2015.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics